(Q34324978)

1 August 2017

1 reference

title

Towards the rational design of Th1 adjuvants (English)

1 reference

1 August 2017

Moingeon P

1 reference

1 August 2017

Haensler J

series ordinal

1 reference

1 August 2017

Lindberg A

series ordinal

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

1 August 2017

1 reference

1 August 2017

1 reference

1 August 2017

1 reference

1 August 2017

page(s)

4363-4372

1 reference

Aluminum compounds used as adjuvants in vaccines

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminium-containing adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Vaccines against intracellular infections requiring cellular immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Adjuvants--a classification and review of their modes of action

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Genetically derived toxoids for use as vaccines and adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Immunological concepts of vaccine adjuvant activity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Immunotherapy of Recurrent Genital Herpes with Recombinant Herpes Simplex Virus Type 2 Glycoproteins D and B: Results of a Placebo‐Controlled Vaccine Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Summary of a clinical trial with liposome-adjuvanted influenza A virus vaccine in elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Immunogenicity and protectivity of a new liposomal hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Booster vaccination against diphtheria and tetanus in man. Comparison of three different vaccine formulations--III

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Adjuvant action of cholera toxin and pertussis toxin in the induction of IgA antibody response to orally administered antigen.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

New perspectives on immunobiology and immunotherapy of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Immune responses to V antigen of Yersinia pestis co-encapsulated with IFN-$gamma;: effect of dose and formulation

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Mobilizing dendritic cells for tolerance, priming, and chronic inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Dendritic cells are recruited into the airway epithelium during the inflammatory response to a broad spectrum of stimuli

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Endotoxin opens the Tollgates to innate immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Bacterial CpG DNA activates immune cells to signal infectious danger.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Chemokines: a new classification system and their role in immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Maturation, activation, and protection of dendritic cells induced by double-stranded RNA

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Anti-interleukin 10 receptor monoclonal antibody is an adjuvant for T helper cell type 1 responses to soluble antigen only in the presence of lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Molecular mapping and detoxification of the lipid A binding site by synthetic peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Immunology. A Toll for DNA vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Presentation of self and microbial lipids by CD1 molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Natural adjuvants: endogenous activators of dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Dendritic cell maturation is induced by mycoplasma infection but not by necrotic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Prevention of peripheral tolerance by a dendritic cell growth factor: flt3 ligand as an adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Flt3 ligand induces tumor regression and antitumor immune responses in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Dendritic cell chemotaxis and transendothelial migration are induced by distinct chemokines and are regulated on maturation

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Expression of a mannose/fucose membrane lectin on human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Human CD14 mediates recognition and phagocytosis of apoptotic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Origin, maturation and antigen presenting function of dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

T-cell co-stimulation through B7RP-1 and ICOS

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

Costimulatory wars: the tumor menace

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

From synapses to immunological memory: the role of sustained T cell stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900193-1

7 January 2021

10.1016/S0264-410X(01)00193-1

Identifiers

DOI

1 reference

1 August 2017

1 reference